Patient-Reported Outcomes in the Treatment of IgA Nephropathy

EP: 1.Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations

EP: 2.Introduction to IgA Nephropathy

EP: 3.Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines

EP: 4.Diagnosing IgA Nephropathy

EP: 5.Signs and Symptoms of IgA Nephropathy

EP: 6.Challenges in Timely Identification of IgA Nephropathy

EP: 7.Clinical Impact of IgA Nephropathy and Quality of Life

EP: 8.Overview of Treatment Landscape for IgA Nephropathy: Standard of Care and KDIGO Guidelines

EP: 9.Current Treatments for IgA Nephropathy and the 4-Hit Cascade

EP: 10.Gaps in Patient Care for IgA Nephropathy

EP: 11.Emerging Anti-BAFF and Anti-APRIL Therapies

EP: 12.Emerging Therapies: Other Strategies and Important Considerations

EP: 13.The Promise of Emerging Therapies for IgA Nephropathy and Future KDIGO Guidelines

EP: 14.Sequencing and Individualizing Treatments for IgA Nephropathy

EP: 15.Measuring Success in IgA Nephropathy in Clinical Practice

EP: 16.Economic Impact of IgA Nephropathy for Patients

EP: 17.Early Diagnosis and Cost Mitigation in IgA Nephropathy

EP: 18.Cost Implications of Modulating IgA Nephropathy Disease Course

Now Viewing

EP: 19.Patient-Reported Outcomes in the Treatment of IgA Nephropathy

EP: 20.Future Possibilities for Step Therapy in IgA Nephropathy Treatment

EP: 21.Key Managed Care Considerations for IgA Nephropathy Treatment

EP: 22.Key Economic Considerations in IgA Nephropathy: Progression to Chronic Kidney Disease

EP: 23.Closing Thoughts About IgA Nephropathy Treatment

Patient-Reported Outcomes in IgA Nephropathy Treatment Evaluation

Critical Patient-Reported Domains

Symptom Management

• Fatigue assessment: Severity, impact on daily activities, and improvement with therapy
• Energy levels: Changes in vitality and stamina for routine tasks
• Edema-related discomfort: Swelling, tightness, and physical restrictions
• Pain during hematuria episodes: Intensity and duration of flank or abdominal discomfort
• Sleep quality: Disruption from nocturia, anxiety, or physical symptoms

Functional Capacity

• Work productivity: Ability to maintain employment, attendance, and performance
• Physical functioning: Capacity for exercise, household activities, and self-care
• Cognitive function: Clarity of thinking and concentration with progressive disease
• Social engagement: Participation in family events and community activities
• Travel limitations: Impact of disease on mobility and travel independence

Psychological Well-Being

• Disease uncertainty anxiety: Concerns about unpredictable progression
• Treatment burden: Mental load of medication adherence and appointments
• Depression screening: Mood impact of chronic disease diagnosis
• Body image concerns: Related to edema, medication adverse effects, or future dialysis access
• Sense of control: Patient empowerment in disease management

Treatment Experience

• Medication adverse effects: Tolerability of prescribed therapies
• Treatment satisfaction: Perceived benefit relative to burden
• Health care interaction quality: Communication effectiveness with providers
• Treatment convenience: Impact of therapy schedule on daily routines
• Financial toxicity: Economic burden of treatment regimens

Implementation Considerations

• Systematic assessment: Integration of validated patient-reported outcome (PRO) measures into routine clinical workflows
• Measurement frequency: Regular scheduled evaluation at meaningful intervals
• Action thresholds: Defined parameters for intervention based on PRO results
• Shared decision-making: Using PRO data to guide treatment choices
• Comparative effectiveness: Inclusion of PROs in evaluating therapeutic options

Prioritizing these patient-centered outcomes alongside traditional clinical end points provides a more comprehensive assessment of treatment value and supports therapeutic decision-making that aligns with patients’ priorities and quality of life goals.